Now that the 2006 midterm elections are over, the pharmaceutical industry is left to ponder what the new Congress has in store for it. This article is a summary of a Pharma Marketing Roundtable discussion of the Congressional agenda for pharma (real and feared). The article includes results from the online "What's In Store From Congress" survey.
